<DOC>
	<DOCNO>NCT01332513</DOCNO>
	<brief_summary>This open-label , single centre , repeat dose , up- titration study healthy male female subject assess pharmacokinetic ( PK ) performance five prototype ezogabine modify release tablet formulation . The study consist screening period , treatment phase ( consist titration phase , bioavailability phase food effect phase ) post-treatment follow-up visit . The study duration screen follow approximately 7 week . No study procedures start inform consent obtain . Subjects remain clinical unit duration treatment period ( 35 day ) . Subjects receive repeat dos ezogabine 34 day start dose 100 mg IR TID ( 300mg TDD ) standard meal ( consume 30 min prior dose ) Days 1-3 , day 4-6 subject receive 150mg IR TID ( 450mg TDD ) . On Day 7 end study subject receive ezogabine ( Mr IR ) dose 600mgTDD . On Day 7 subject enter 6-way cross period investigate 5 MR formulation test ( 300mg BID ) single IR formulation ( 200mg TID ) . Subjects receive formulaition 4 day blood sample pharmacokinetic analysis collect 24 hour post dose 4th day ( PK day ) . On Day 31 subject enter food effect phase investigate 5 MR formulation test ( 600mg QD ) . Subjects period PK day Day 33 ( follow standard breakfast ) , Day 34 ( follow high fat breakfast ) investigate food effect PK profile ezogabine .</brief_summary>
	<brief_title>An Open Label , Randomised , Repeat Dose Study Assess Pharmacokinetic Performance Five Ezogabine/Retigabine Modified Release ( MR ) Formulations Steady State Compared Immediate Release ( IR ) Formulation .</brief_title>
	<detailed_description />
	<mesh_term>Ezogabine</mesh_term>
	<criteria>1 . Healthy determine responsible experienced physician 2 . Male female 18 60 year age inclusive , time signing informed consent . 3 . A female subject eligible participate : Nonchildbearing potential define Childbearing potential agrees use one contraception method list 4 . Male subject must agree use one contraception method list 5 . Body weight &gt; 50 kg body mass index ( BMI ) within range 18 30kg/m2 ( inclusive ) . 6 . Normal High Normal blood pressure 7 . 24hr holter clinically significant finding . 8 . QTcB QTcF &lt; 450 msec screen predose . 9 . Creatinine Clearance within normal range screen predose . 10 . Liver function test within normal limit screen predose . 11 . Capable give write informed consent , include compliance requirement restriction list consent form . A subject eligible inclusion study follow criterion apply : 1 . Subjects vegetarian vegan , reason unwilling consume high fat meal . 2 . The subject either previous disease current medical condition 3 . Has make suicide attempt past , investigator 's judgment , pose significant suicide risk . 4 . Presence clinically significant proteinuria hematuria clinically significant finding urinalysis . 5 . Subjects symptoms urinary dysfunction . 6 . Subjects whose ECG show PR interval &gt; 220 msec , presence intraventricular conduction disturbance ( complete incomplete BBB ) , screen prior dosing . 7 . Presence clinically significant arrhythmia . 8 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 9 . Current chronic liver disease biliary abnormality . Medical history positive biliary sign symptom ( cholecystectomy acceptable ) . 10 . History regular alcohol consumption within 6 month study . 11 . A positive drug/alcohol screen screen / predose . 12 . A positive test HIV antibody . 13 . The subject smoke 10 cigarette per week . 14 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 15 . Exposure four new chemical entity within 12 month prior first dose day . 16 . Use prescription nonprescription drug . 17 . History sensitivity study medication , component thereof history drug allergy . 18 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 19 . Pregnant female determine positive serum hCG test screen prior dosing . 20 . Lactating female . 21 . Unwillingness inability follow procedure outline protocol . 22 . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>